Thalidomide and immunomodulatory drugs in the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 14, Issue 1, 2005, Pages 45-55

  Bamias, Aristotle ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Cancer; CC 4047; CC 5013; ImiD; Myeloma; Thalidomide

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CARMUSTINE; CISPLATIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENMD 0995; ETOPOSIDE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 2; IRINOTECAN; LAXATIVE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TEMOZOLOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AMYLOIDOSIS; ANTIANGIOGENIC ACTIVITY; BLOOD TRANSFUSION; BONE MARROW TOXICITY; BRADYCARDIA; BRAIN TUMOR; CACHEXIA; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HIGH FIBER DIET; HUMAN; HYPOTHYROIDISM; IMMUNOMODULATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIBIDO DISORDER; MELANOMA; MENSTRUATION DISORDER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; NEUTROPENIA; NONHUMAN; PHOCOMELIA; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SEDATION; SENSORY NEUROPATHY; SOMNOLENCE; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TREMOR; WALDENSTROEM MACROGLOBULINEMIA; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; NERVOUS SYSTEM DISEASES; THALIDOMIDE;

EID: 12744272165     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.1.45     Document Type: Review

References (88)

1. D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082-4085.
2. ZWINGENBERGER K, WNEND S: Immunomodulation by thalidomide: systemic review of the literature and of unpublished observations. J. Inflamm. (1995) 46:177-221.
3. RICHARDSON P, HIDERSHIMA T, ANDERSON K: Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. (2002) 53:629-657.
4. STIRLING DI: Pharmacology of thalidomide. Semin. Hematol. (2000) 37(Suppl. 3):5-14.
5. FIGG WD, RAJE S, BAUER KS et al.: Pharmacokinetics of thalidomide in an elderly prostate cancer population. J. Pharm. Sci. (1999) 88:121-125.
6. FRANKS ME, MacPHERSON GR, FIGG WD: Thalidomide. Lancet (2004) 363:1802-1811.
7. HERNBERG M, VIRKKUNEN P, BONO P, AHTINEN H, MAENPAA H, JOENSUU H: Interferon-α-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J. Clin. Oncol. (2003) 21:3770-3776.
8. PRO B, YOUNES A, ALBITAR M et al.: Thalidomide for patients with recurrent lymphoma. Cancer (2004) 100 1186-1189.
9. SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341:1565-1571.
10. THOMPSON MA, WITZIG TE, KUMAR S et al.: Plasma levels of tumor necrosis factor α and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br. J. Haematol. (2003) 123 305-308.
11. MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A et al.: Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. (1993) 177 1675-1680.
12. KEIFER JA, GUTTRIDGE DC, ASHBURNER BP, BALDWIN AS: Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J. Biol. Chem. (2001) 276:22383-22387.
13. + cells' ability to incorporate [H3]-thymidine-dependence on the primary stimulant. Int. Immunopharmacol. (2002) 2 1143-1153.
14. +) T cells. Clin. Exp. Immunol. (2002) 130:75-84.
15. FUJITA J, MESTRE JR, ZELIDIS JB, SUBBARAMAIAH K, DANNENBERG AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res. (2001) 7:3349-3355.
16. GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 31:213-221.
17. CAVENAGH JD, OAKERVEE H. Thalidomide in multiple myeloma: current status and future prospects. Br. J. Haematol. (2003) 120 18-26.
18. BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification and prognostic factors in a Phase II study of 169 patients. Blood (2001) 98:492-494.
19. DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. (2001) 12:991-995.
20. PLUMBO A, GIACCONE L, BERTOLA A et al.: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica (2001) 86:399-403.
21. MOEHLER TM, NEBEN K, BENNER A et al.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 98:3846-3848.
22. KROPFF MH, LANG N, BISPING G et al.: Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br. J. Haematol. (2003) 122:607-616.
23. LEE CK, BARLOGIE B, MUSHNI N et al.: DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J. Clin. Oncol. (2003) 21 2732-2739.
24. RAJKUMAR SV, GERTZ MA, LACY MQ, DISPENZIERI A et al.: Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 17:775-779.
25. WEBER D, RANKIN K, GAVINO M et al.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. (2003) 21:16-19.
26. RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. (2002) 20:4319-4323.
27. RAJKUMAR SV, BLOOD E, VESOLE DH, SHEPARD R, GREIPP RP: A randomised Phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group. Proc. ASCO (2004):558 (Abstract 6508).
28. ZERVAS K, DIMOPOULOS MA, HATZICHARISSI E et al.: Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol. (2004) 15:134-138.
29. GOLDSCHMIDT H, SONNEVELD P, CREMER FW et al.: Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintainance treatment for newly diagnosed myeloma patients. Ann. Hematol. (2003) 82:654-659.
30. ZANGARI MA, ANASSIE E, RARLOGIE B et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 98:1614-1615.
31. ALEXANIAN R, WEBER D, GIRALT S, DELASALLE K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann. Oncol. (2002) 13:1116-1119.
32. DIMOPOULOS MA. TSATALAS C, ZOMAS A et al.: Treatment of Waldenstrom's Macroglobulinemia with single agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin. Oncol. (2003) 30:265-269.
33. DIMOPOULOS MA, ZOMAS A, VINIOU NA C et al.: Treatment of Waldenstrom's macroglobulinemia with thalidomide. J. Clin. Oncol. (2001) 19:3596-3601.
34. SELDIN DC, CHOUFANI EB, DEMBER LM et al.: Tolerability and efficacy of thalidomide for the treatment of patients with AL amyloidosis. Clin. Lymphoma (2003) 3:241-246.
35. PALLADINI G, PERFETTI V, OBICI L et al.: Thalidomide toxicity in patients with AL (primary) amyloidosis. Blood (2002) 100:397a (Abstract 1543).
36. ELLIOTT MA, MESA RA, LI CY et al.: Thalidomide treatment in myelofibrosis writh myeloid metaplasia. Br. J. Haematol. (2002) 117:288-296.
37. MARCHETTI M, BAROSI G, BALESTRI F et al.: Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a Phase II trial. J. Clin. Oncol. (2004) 22 424-431.
38. MESA RA, STEENSMA DP, PARDANANI A et al.: A Phase II trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood (2003) 101:2534-2541.
39. RAZA A, MEYER P, DUTT D et al.: Thalidomide produces transfusion-independence in long-standing refractory anaemias of patients with myelodysplastic syndromes. Blood (2001) 98:958-965.
40. CORTES J, KANTARJIAN H, ALBITAR M et al.: A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myeloid leukemia or myelodysplastic syndrome. Cancer (2003) 97:1234-1241.
41. STEINS MB, PADRO T, BIEKER R et al.: Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood (2002) 99:834-839.
42. THOMAS D, ESTEY E, GILES FJ et al.: Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br. J. Haematol. (2003) 123:436-441.
43. FINE HA, FIGG WD, JAECKLE K et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent highgrade gliomas. J. Clin. Oncol. (2000) 18:708-715.
44. SHORT SC, TRAISH D, DOWE A, HINES F, GORE M, BRADA M: Thalidomide as an antiangiogenic agent relapsed gliomas. J. Neurooncol. (2001) 51:41-45.
45. MARX GM, PAVLAKIS N, McCOWATT S et al.: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. (2001) 54:31-38.
46. FINE HA, WEN PY, MAHER EA et al.: Phase II trial of thalidomide and carmustine for patients with high grade gliomas. J. Clin. Oncol. (2003) 21:2299-2304.
47. BAUMANN F, BJELJAC M, KOLLIAS SS et al.: Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J. Neurooncol. (2004) 67:191-200.
48. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
49. STEBBING J, BENSON C, EISEN T et al.: The treatment of advanced renal cell cancer with high dose oral thalidomide. Br. J. Cancer (2001) 85:953-958.
50. MOTZER RJ, BERG W, GINSBERG M et al.: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol. (2002) 20:302-306.
51. ESCUDIER B, LASSAU N, COUANET D et al.: Phase II trial of thalidomide in renal-cell carcinoma. Ann. Oncol. (2002) 13 1029-1035.
52. NATHAN PD, GORE ME, EISEN TG: Unexpected toxicity of combination thalidomide and interferon α-2a treatment in metastatic renal cell carcinoma. J. Clin. Oncol. (2002) 20:1429-1430.
53. ELARAJ DM, WHITE DE, STEINBERG SM, HAWORTH L, ROSENBERG SA, YANG JC: A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J. Immunother. (2004) 27:259-264.
54. DRAKE MJ, ROBSON W, MEHTA P, SCOFIELD I, NEAL DE, LEUNG HY: An open-label Phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br. J. Cancer (2003) 88 822-827.
55. FIGG WD, DAHUT W, DURAY P et al.: A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. (2001) 7 1888-1893.
56. DAHUT WL, GULLEY JL, ARLEN PM et al.: Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22:2532-2539.
57. EISENBERGER MA, DEWIT R, BERRY W et al. A multicenter Phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). J. Clin. Oncol. (2004) 22(Suppl. 14S):2s (Abstract 4).
58. PETRYLAK DP, TANGEN C, HUSSAIN M et al.: SWOG 99-16: randomized Phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (p) in men with androgen-independent prostate cancer (AIPCA). J. Clin. Oncol. (2004) 22(Suppl. 14S):2s (Abstract 3).
59. HWU WJ, KROWN SE, PANAGEAS KS et al.: Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J. Clin. Oncol. (2002) 20:2610-2615.
60. HWU WJ, KROWN SE, MENELL JH et al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. (2003) 21:3351-3356.
61. DANSON S, LORIGAN P, ARANCE A et al.: Randomized Phase II study of temozolomide given every 8 hours or daily with either interferon α-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol. (2003) 21:2551-2557
62. HUTCHINS L, MOON J, CLARK J, THOMPSON J, YOST K, SONDAK V: Interferon α-2b and thalidomide in previously treated patients with disseminated malignant melanoma. a SWOG 0026. Proc. ASCO (2004 :713 (Abstract 7527).
63. FIFE K, HOWARD MR, GRACIE F, PHILLIPS RH, BOWER R: Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int. J. STD AIDS (1998) 9:751-755.
64. LITTLE RF, WYVILL KM, PLUDA JM et al.: Activity of thalidomide in AIDS-Related Kaposi sarcoma. J. Clin. Oncol. (2000) 18:2593-2602.
65. BAIDAS SM, WINER EP, FLEMING GF: Phase II evaluation of thalidomide in patients with metastatic breast cancer J. Clin. Oncol. (2000) 18:2710-2717.
66. HSU C, CHEN CN, CHEN LT et al.: Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology (2003) 65:242-249.
67. TSENG JE, GLISSON BS, KHURI FR et al.: Phase II study of the antiangiogenic agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer (2001) 92 2364-2373.
68. DRACH J, KAUFMANN H, WOEHRER S, CHOTT A, ZIELINSKI ZZ, RADERER M: Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma. Proc. ASCO (2004):576 (Abstract 6583).
69. HURWITZ H, FEHRENRACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
70. ROVELLI A, ARRIGO C, NESI F et al.: The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant (1998) 21:577-81.
71. KULKARNI S, POWLES R, SIROHI B et al.: Thalidomide after allogenic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant. (2003) 32:165-170.
72. KAPLAN G, THOMAS S, FIERRER DS et al.: Thalidomide for the treatment of AIDS-associated wasting. AIDS Res. Hum. Retroviruses (2000) 16:1345-1355.
73. BRUERA E, NEUMANN CM, PITUSKIN E, CALDER K, BALL G, HANSON J: Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Ann. Oncol. (1999) 10:857-859.
74. ZELDIS JB, WILLIAMS BA, THOMAS SD, ELSAYED ME: S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin. Ther. (1999) 21:319-320.
75. ZANGARI M, BARLOGIE B, THERTULIEN R et al.: Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin. Lymphoma (2003) 4:32-35.
76. CHAUNDRI V, CORNBLATH DR, CORSE A, FREIMER M, SIMMONS-O'BRIEN E, VOGELSANG G: Thalidomide-induced neuropathy. Neurology (2002) 59:1872-1875.
77. DREDGE K, MARRIOTT JB, MacDONALD CD et al.: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. J. Cancer (2002) 87:1166-1172.
78. MARRIOTT JB, CLARKE IA, CZAJKA A et al.: A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res. (2003) 63:593-599.
79. DIMOPOULOS MA, ANAGNOSTOPOULOS A, WEBER D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J. Clin. Oncol. (2003) 21:4444-4454.
80. LENTZSCH S, LEBLANC R, PODAR K, DAVIES F, LIN B, HIDESHIMA T et al.: Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia (2003) 17 41-44.
81. BARTLETT JB, MICHAEL A, CLARKE IA et al.: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer (2004) 90 955-961.
82. SCHEY SA, FIELDS P, BARTLETT JB et al.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. (2004) 22 3269-3276.
83. DREDGE K, MARRIOTT JB, TODRYK SM et al.: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. (2002) 168:4914-4919.
84. SIROHI B, POWLES R: Multiple myeloma. Lancet (2004) 363:875-887.
85. RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100:3063-3067.
86. ZANGARI M, TRICOT G, ZELDIS J et al.: Results of Phase I study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose therapy. Blood (2001) 98:775a (Abstract 3226).
87. RICHARDSON PG, JAGANNAH S, SCHLOSSMAN RL et al.: A multi-center randomized, Phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for die treatment of relapsed or refractory multiple myeloma. Blood (2002) 100:104a (Abstract 386).
88. BARLOGIE, B: Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin. Hematol. (2003) 40 33-38.